Compare QTTB & ASLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QTTB | ASLE |
|---|---|---|
| Founded | 2015 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 265.2M | 219.1M |
| IPO Year | 2018 | 2018 |
| Metric | QTTB | ASLE |
|---|---|---|
| Price | $8.51 | $5.00 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 2 |
| Target Price | ★ $39.67 | $5.75 |
| AVG Volume (30 Days) | 322.9K | ★ 350.1K |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 136.78 | 63.64 |
| EPS | N/A | ★ N/A |
| Revenue | $53,737,000.00 | ★ $335,286,000.00 |
| Revenue This Year | N/A | $4.24 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.93 | $4.52 |
| 52 Week High | $23.57 | $7.93 |
| Indicator | QTTB | ASLE |
|---|---|---|
| Relative Strength Index (RSI) | 41.77 | 48.59 |
| Support Level | $8.23 | $4.53 |
| Resistance Level | $9.41 | $5.26 |
| Average True Range (ATR) | 0.54 | 0.25 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 20.24 | 47.98 |
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).
AerSale Corp offers full-service support to owners and operators of mid-life commercial aircraft. It specializes in the sale, lease, and exchange of used aircraft, engines, and components, in addition to providing various maintenance, repair, and overhaul, and engineering services for commercial aircraft and components. AerSale also offers asset management services to owners of end-of-life aircraft and engine portfolios. The company has two reportable segments: Asset Management Solutions and TechOps. Maximum revenue is generated from the Asset Management Solutions segment, which comprises activities to extract value from strategic asset acquisitions through leasing, trading, or disassembling for product sales. Geographically, the company derives maximum revenue from its domestic market.